Veracyte www.veracyte.com 
是一家在新興的分子細(xì)胞學(xué)領(lǐng)域處于領(lǐng)先水平的分子診斷公司。Afirma基因表達(dá)檢測(cè)可減少不必要的甲狀腺癌手術(shù)風(fēng)險(xiǎn),通過(guò)基因表達(dá)分類(lèi)器檢測(cè)Afirma基因的表達(dá)能降低超過(guò)一半以上不必要的甲狀腺癌手術(shù)。

Veracyte, Inc., based in South San Francisco, Calif., is a privately held molecular diagnostics company pioneering the field of molecular cytology. The company is focused on discovering, developing and commercializing molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first product – the Afirma Thyroid FNA Analysis – was launched in 2011 and combines specialized cytopathology assessment with the Afirma Gene Expression Classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer. The company has a global co-promotion agreement with Genzyme, a Sanofi company, to make the Afirma Thyroid FNA Analysis more broadly available. Veracyte is privately held and funded by Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures. Veracyte and Afirma are registered trademarks of Veracyte, Inc. All rights reserved.